InvestorsHub Logo
Followers 53
Posts 1782
Boards Moderated 0
Alias Born 03/22/2015

Re: Chasing post# 308098

Friday, 01/18/2019 7:13:33 AM

Friday, January 18, 2019 7:13:33 AM

Post# of 402252

The topic was Purdue buying Elite, people. The topic was not about a licensing agreement with Elite. 2 monumentally different concepts. Please stop conflating.

My Guess is Purdue Will Buy This

Everyone, please notice Elite has branched out in the last 14.5 years, not to mention many companies have even changed their minds over the course of 14.5 years.







Oh, right, Chasing, I forgot about out our trimipramine ANDA. And our generic Adderall tech, which is only shared with a dozen competitors. As a non-delusional investor who prefers fact-based due diligence, I understand that Purdue is much more likely to **SUE** Elite than they are to **BUY** Elite. They already own an antagonist ADF patent, and they get a royalty from Pfizer for every tablet of Embeda sold. Some have argued that is why Pfizer never launched Troxyca, because they would rather see it die on the vine than give Purdue another nickel. Purdue was smart enough to know there were stability problems with the one bead system, and so they never developed it. They did, however, let Alpharma and Pfizer spend millions getting Embeda approved and then successfully sued them as soon as they could. The safest assumption for proper due diligence is that Purdue, a well-known vigorous defender of their patents, is going to sue Elite if the company were to ever get approval for SequestOx. Ignoring this possibility is to ignore reality, and I'm sure Nasrat has considered the cost of a legal battle with Purdue in his decision-making regarding ongoing SequestOx development.



I know what I have here. I have a cGMP and DEA-certified pharmaceutical factory that is currently under utilized. If the company can successfully increase the output of the factory with controlled substances and other high-margin drugs that cannot be manufactured more cheaply overseas, then we could eventually reach profitably in the range of hundreds of millions of dollars and a share price of multiple dollars. I do not fantasize about buyouts from big boys who would rather crush us than own us.





Call on God but row away from the rocks.

-Hunter S. Thompson

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News